Pharmascience Welcomes Canadian Ruling On Nitrosamines
Class Action Related To Presence Of NDMA In Ranitidine Dismissed
Executive Summary
Pharmascience was among the firms that were named in a class action lawsuit in Canada over the presence of nitrosamine NDMA in ranitidine. Now, the company has welcomed a summary judgement decision by the Supreme Court of British Columbia to dismiss the claims.
You may also be interested in...
UAE’s Bioventure Is Looking For Partners To Expand
Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.
Medicines For Europe Highlights Industry Agenda
Ahead of its annual meeting in Malta in mid-June, European off-patent industry association Medicines for Europe has set out the hot topics for generics and biosimilars stakeholders that delegates will be looking to discuss.
Who’s Hired? New Mithra CEO Mulls Selling Generics Business
Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.